Low grade serous ovarian carcinoma

identifying variations in practice patterns

John Siemon, David M. Gershenson, Brian Slomovitz, Matthew Schlumbrecht

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Low grade serous ovarian carcinoma is a rare subtype of ovarian cancer with an indolent and chemorefractory course. As such, treatment strategies among practitioners are not uniformly known. The primary objective of this study was to identify differences in practice patterns among physicians who treat low grade serous carcinoma. METHODS MATERIALS: A de novo survey was distributed to members of the Society of Gynecologic Oncology. Questions about demographics, management of primary and recurrent disease, and use of consolidation therapy were included. Statistical analyses were performed using χ2 and Fisher's exact tests. RESULTS: 194 gynecologic oncologists completed the survey. Approximately two-thirds of respondents practiced in a university based setting and treated a high volume of ovarian cancers, including low grade serous carcinoma. 82% recommended somatic testing during treatment and 84% routinely sent patients for genetic counseling. Treatment preferences for primary disease varied by debulking status. 48% of practitioners used hormone antagonism as consolidation after primary treatment. Secondary cytoreduction was preferred for patients with platinum sensitive recurrence and a long disease free interval following primary treatment (P<0.001). Hormone antagonism was the preferred treatment for the first platinum resistant recurrence (54%), while a BRAF inhibitor was the preferred agent in platinum resistant recurrence in the presence of a known BRAF mutation (56%). CONCLUSIONS: There was significant variation in the preferred management of low grade serous carcinoma among practitioners. Further efforts to improve knowledge of this disease, identify optimal treatment modalities, and provide guidelines for management should be encouraged.

Original languageEnglish (US)
Pages (from-to)174-180
Number of pages7
JournalInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Carcinoma
Platinum
Therapeutics
Recurrence
Ovarian Neoplasms
Physicians' Practice Patterns
Hormones
Genetic Counseling
Demography
Guidelines
Mutation
Surveys and Questionnaires

Keywords

  • low grade
  • ovarian carcinoma
  • practice patterns
  • serous
  • survey

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Low grade serous ovarian carcinoma : identifying variations in practice patterns. / Siemon, John; Gershenson, David M.; Slomovitz, Brian; Schlumbrecht, Matthew.

In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 29, No. 1, 01.01.2019, p. 174-180.

Research output: Contribution to journalArticle

@article{5265e7f132ef4cf58be522bf1a59c856,
title = "Low grade serous ovarian carcinoma: identifying variations in practice patterns",
abstract = "OBJECTIVES: Low grade serous ovarian carcinoma is a rare subtype of ovarian cancer with an indolent and chemorefractory course. As such, treatment strategies among practitioners are not uniformly known. The primary objective of this study was to identify differences in practice patterns among physicians who treat low grade serous carcinoma. METHODS MATERIALS: A de novo survey was distributed to members of the Society of Gynecologic Oncology. Questions about demographics, management of primary and recurrent disease, and use of consolidation therapy were included. Statistical analyses were performed using χ2 and Fisher's exact tests. RESULTS: 194 gynecologic oncologists completed the survey. Approximately two-thirds of respondents practiced in a university based setting and treated a high volume of ovarian cancers, including low grade serous carcinoma. 82{\%} recommended somatic testing during treatment and 84{\%} routinely sent patients for genetic counseling. Treatment preferences for primary disease varied by debulking status. 48{\%} of practitioners used hormone antagonism as consolidation after primary treatment. Secondary cytoreduction was preferred for patients with platinum sensitive recurrence and a long disease free interval following primary treatment (P<0.001). Hormone antagonism was the preferred treatment for the first platinum resistant recurrence (54{\%}), while a BRAF inhibitor was the preferred agent in platinum resistant recurrence in the presence of a known BRAF mutation (56{\%}). CONCLUSIONS: There was significant variation in the preferred management of low grade serous carcinoma among practitioners. Further efforts to improve knowledge of this disease, identify optimal treatment modalities, and provide guidelines for management should be encouraged.",
keywords = "low grade, ovarian carcinoma, practice patterns, serous, survey",
author = "John Siemon and Gershenson, {David M.} and Brian Slomovitz and Matthew Schlumbrecht",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/ijgc-2018-000018",
language = "English (US)",
volume = "29",
pages = "174--180",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Low grade serous ovarian carcinoma

T2 - identifying variations in practice patterns

AU - Siemon, John

AU - Gershenson, David M.

AU - Slomovitz, Brian

AU - Schlumbrecht, Matthew

PY - 2019/1/1

Y1 - 2019/1/1

N2 - OBJECTIVES: Low grade serous ovarian carcinoma is a rare subtype of ovarian cancer with an indolent and chemorefractory course. As such, treatment strategies among practitioners are not uniformly known. The primary objective of this study was to identify differences in practice patterns among physicians who treat low grade serous carcinoma. METHODS MATERIALS: A de novo survey was distributed to members of the Society of Gynecologic Oncology. Questions about demographics, management of primary and recurrent disease, and use of consolidation therapy were included. Statistical analyses were performed using χ2 and Fisher's exact tests. RESULTS: 194 gynecologic oncologists completed the survey. Approximately two-thirds of respondents practiced in a university based setting and treated a high volume of ovarian cancers, including low grade serous carcinoma. 82% recommended somatic testing during treatment and 84% routinely sent patients for genetic counseling. Treatment preferences for primary disease varied by debulking status. 48% of practitioners used hormone antagonism as consolidation after primary treatment. Secondary cytoreduction was preferred for patients with platinum sensitive recurrence and a long disease free interval following primary treatment (P<0.001). Hormone antagonism was the preferred treatment for the first platinum resistant recurrence (54%), while a BRAF inhibitor was the preferred agent in platinum resistant recurrence in the presence of a known BRAF mutation (56%). CONCLUSIONS: There was significant variation in the preferred management of low grade serous carcinoma among practitioners. Further efforts to improve knowledge of this disease, identify optimal treatment modalities, and provide guidelines for management should be encouraged.

AB - OBJECTIVES: Low grade serous ovarian carcinoma is a rare subtype of ovarian cancer with an indolent and chemorefractory course. As such, treatment strategies among practitioners are not uniformly known. The primary objective of this study was to identify differences in practice patterns among physicians who treat low grade serous carcinoma. METHODS MATERIALS: A de novo survey was distributed to members of the Society of Gynecologic Oncology. Questions about demographics, management of primary and recurrent disease, and use of consolidation therapy were included. Statistical analyses were performed using χ2 and Fisher's exact tests. RESULTS: 194 gynecologic oncologists completed the survey. Approximately two-thirds of respondents practiced in a university based setting and treated a high volume of ovarian cancers, including low grade serous carcinoma. 82% recommended somatic testing during treatment and 84% routinely sent patients for genetic counseling. Treatment preferences for primary disease varied by debulking status. 48% of practitioners used hormone antagonism as consolidation after primary treatment. Secondary cytoreduction was preferred for patients with platinum sensitive recurrence and a long disease free interval following primary treatment (P<0.001). Hormone antagonism was the preferred treatment for the first platinum resistant recurrence (54%), while a BRAF inhibitor was the preferred agent in platinum resistant recurrence in the presence of a known BRAF mutation (56%). CONCLUSIONS: There was significant variation in the preferred management of low grade serous carcinoma among practitioners. Further efforts to improve knowledge of this disease, identify optimal treatment modalities, and provide guidelines for management should be encouraged.

KW - low grade

KW - ovarian carcinoma

KW - practice patterns

KW - serous

KW - survey

UR - http://www.scopus.com/inward/record.url?scp=85060007567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060007567&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2018-000018

DO - 10.1136/ijgc-2018-000018

M3 - Article

VL - 29

SP - 174

EP - 180

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -